2',3'-Dihydroxy Propyl Pentadecanoate

2',3'-Dihydroxy Propyl Pentadecanoate

SCHEMBL401287

CCCCCCCCCCCCCCC(=O)OCC(O)CO

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 1.00
KDM4E B2RXH2 1/20 1.00
DUSP3 P51452 1/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
DGKA P23743 1/20 0.82
MAPT P10636 1/20 0.69
FAAH O00519 2/20 0.68
PRKCA P17252 3/20 0.66
PRKCE Q02156 1/20 0.66
PRKCQ Q04759 1/20 0.66
PRKCD Q05655 1/20 0.66
ENPP2 Q13822 4/20 0.65
LPAR6 P43657 1/20 0.65
LPAR1 Q92633 1/20 0.65
LPAR4 Q99677 1/20 0.65
LPAR5 Q9H1C0 1/20 0.65
LPAR2 Q9HBW0 1/20 0.65
LPAR3 Q9UBY5 1/20 0.65
ALDH1A1 P00352 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL526047 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
Monoctanoin Component B SCHEMBL22366087 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
Glycerol Monolaurate SCHEMBL16042 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL595035 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL21685815 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL21685794 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
Octane SCHEMBL5181039 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL3503441 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
Glyceryl Monostearate SCHEMBL5719482 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A
SCHEMBL16538137 1.00 LMNA (1.00) LMNAKDM4EDUSP3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 340 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11839626-B2 Composition and kits for inhibition of pathogenic microbial infection and methods of using the same ROCHAL TECHNOLOGIES LLC (US) 2023-12-12 US claimed
WO-2023160458-A1 CHINESE HERBAL MEDICINE ACTIVE SUBSTANCE @ VESICLE COMPLEX HAVING HAIR CARE AND GROWTH EFFECTS, AND PREPARATION METHOD THEREFOR AND USE THEREOF 山东大学 2023-08-31 WO claimed
EP-4051239-A1 POLOXAMER COMPOSITIONS WITH REDUCED SOL-GEL TRANSITION TEMPERATURES AND METHODS OF REDUCING THE SOL-GEL TRANSITION TEMPERATURE OF POLOXAMER COMPOSITIONS Rochal Technologies LLC (US) 2022-09-07 EP claimed
CN-114929200-A Method for lowering sol-gel transition temperature 罗查尔科技有限责任公司 2022-08-19 CN claimed
WO-2021086698-A1 METHODS FOR REDUCING THE TEMPERATURE OF SOL-GEL TRANSITIONS ROCHAL INDUSTRIES, LLC (US) 2021-05-06 WO claimed
US-20210121575-A1 Poloxamer Compositions With Reduced Sol-Gel Transition Temperatures and Methods of Reducing the Sol-Gel Transition Temperature of Poloxamer Compositions ROCHAL INDUSTRIES, LLC (US) 2021-04-29 US claimed
EP-2787985-B1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME ROCHAL IND LLC (US) 2020-07-01 EP claimed
US-20190262268-A1 ORAL MODIFIED RELEASE FORMULATIONS RUBICON RES PRIVATE LIMITED (IN) 2019-08-29 US claimed
WO-2018055641-A1 ORAL MODIFIED RELEASE FORMULATIONS RUBICON RESEARCH PRIVATE LIMITED (IN) 2018-03-29 WO claimed
US-20170360825-A1 Composition and Kits for Inhibition of Pathogenic Microbial Infection and Methods of Using the Same ROCHAL INDUSTRIES, LLC (US) 2017-12-21 US claimed
US-8829053-B2 Biocidal compositions and methods of using the same ROCHAL INDUSTRIES LLP (US) 2014-09-09 US claimed
US-20130309282-A1 HAIRSTYLING AGENT COMPOSITION KIKUBOSHI CORPORATION (JP) 2013-11-21 US claimed
US-20130150451-A1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME ROCHAL INDUSTRIES, LLP (US) 2013-06-13 US claimed
WO-2013086181-A1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME ROCHAL INDUSTRIES, LLP (US) 2013-06-13 WO claimed
WO-2007070561-A2 AGENTS FOR CONTROLLING BIOLOGICAL FLUIDS AND METHODS OF USE THEREOF SOUTHEASTERN MEDICAL TECHNOLOGIES (US) 2007-06-21 WO claimed
WO-2007046577-A1 EXTERNAL COMPOSITION FOR HAIR GROWTH AMOREPACIFIC CORPORATION (KR) 2007-04-26 WO claimed
US-20070059350-A1 Agents for controlling biological fluids and methods of use thereof SOUTHEASTERN MEDICAL TECHNOLOGIES, LLC 2007-03-15 US claimed
US-20070053957-A1 Agents for controlling biological fluids and methods of use thereof SOUTHEASTERN MEDICAL TECHNOLOGIES, LLC 2007-03-08 US claimed
EP-0397211-B1 PERCUTANEOUS ADMINISTRATION OF 3'-AZIDE-3'-DEOXYTHYMIDINE NELSON-SUMISHO Co., Ltd. (JP) 1993-05-12 EP claimed
EP-0397211-A2 Percutaneous administration of 3'-azide-3'-deoxythymidine NELSON-SUMISHO Co., Ltd. (JP) 1990-11-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360825-A1 Composition and Kits for Inhibition of Pathogenic Microbial Infection and Methods of Using the Same CUTA, MMP8, MMP1 LMNA 1237/4885KDM4E 4848/4885DUSP3 1252/4885
US-20210121575-A1 Poloxamer Compositions With Reduced Sol-Gel Transition Temperatures and Methods of Reducing the Sol-Gel Transition Temperature of Poloxamer Compositions PAOX, HPGDS, SPTSSB LMNA 2898/4885KDM4E 4814/4885DUSP3 1255/4885
US-20130150451-A1 BIOCIDAL COMPOSITIONS AND METHODS OF USING THE SAME GCG, BID, DGAT1 LMNA 4213/4885KDM4E 3836/4885DUSP3 141/4885
US-11839626-B2 Composition and kits for inhibition of pathogenic microbial infection and methods of using the same CUTA, MMP8, MMP1 LMNA 1237/4885KDM4E 4848/4885DUSP3 1252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.